Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Down – What’s Next?

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) gapped down prior to trading on Thursday . The stock had previously closed at $47.67, but opened at $44.75. Kymera Therapeutics shares last traded at $46.18, with a volume of 55,106 shares changing hands.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the company. B. Riley lifted their price objective on Kymera Therapeutics from $31.00 to $36.00 and gave the stock a “neutral” rating in a research report on Tuesday, July 9th. Wells Fargo & Company lifted their target price on Kymera Therapeutics from $30.00 to $38.00 and gave the stock an “equal weight” rating in a report on Monday, August 12th. Wolfe Research upgraded Kymera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $65.00 price target on the stock in a report on Monday, August 26th. Leerink Partners reiterated an “outperform” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a research note on Monday, September 9th. Finally, Oppenheimer increased their target price on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research note on Friday, September 27th. Four research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $49.15.

Kymera Therapeutics Stock Up 0.6 %

The stock has a market capitalization of $2.87 billion, a P/E ratio of -19.20 and a beta of 2.21. The business’s 50 day simple moving average is $47.04 and its two-hundred day simple moving average is $40.65.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, beating the consensus estimate of ($0.83) by $0.01. The business had revenue of $3.74 million for the quarter, compared to analysts’ expectations of $10.34 million. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The firm’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.90) EPS. Analysts predict that Kymera Therapeutics, Inc. will post -2.85 earnings per share for the current year.

Insider Activity

In related news, Director Jeffrey W. Albers sold 5,000 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total value of $245,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Pamela Esposito sold 13,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total value of $651,780.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Jeffrey W. Albers sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $49.10, for a total value of $245,500.00. The disclosure for this sale can be found here. Corporate insiders own 15.82% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its position in shares of Kymera Therapeutics by 1.8% during the 4th quarter. Vanguard Group Inc. now owns 3,997,564 shares of the company’s stock valued at $101,778,000 after acquiring an additional 72,351 shares during the period. Jennison Associates LLC purchased a new stake in Kymera Therapeutics in the first quarter worth $17,122,000. Bayesian Capital Management LP bought a new stake in shares of Kymera Therapeutics in the first quarter valued at $569,000. Price T Rowe Associates Inc. MD lifted its position in shares of Kymera Therapeutics by 18.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,332,012 shares of the company’s stock valued at $254,548,000 after buying an additional 996,300 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of Kymera Therapeutics by 19.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 156,211 shares of the company’s stock valued at $4,663,000 after buying an additional 25,317 shares during the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.